Imagion Biosystems (ASX:IBX) has announced the appointment of Dianne Angus to its board of directors.
The company, which is focused on the earlier detection of cancer, said Ms Angus brings significant executive managerial and company director experience in the biotechnology, biopharmaceutical, agritech and healthcare industries, including with Neuren Pharmaceuticals and Prana Biotechnology (now Alterity Therapeutics).
The company said Ms Angus has experience in stakeholder relations, corporate governance and compliance, as well as capital raising and corporate strategy. She is a registered patent attorney and a member of the Australian Institute of Company Directors (AICD).
“I am delighted to join the Imagion Biosystems Board as the Company looks to transition its unique technology platform through clinical validation to demonstrate precise and early cancer detection. The MagSense technology has strong credentials to change clinical practice, deliver better patient outcomes and commercial success,” said Ms Angus.
MagSense is a new imaging method with the potential to be more sensitive and safer for detecting cancers and other critical diseases.
According to Bob Proulx, executive chairman of Imagion Biosystems, “We are extremely pleased to welcome Dianne as a fellow director of Imagion. Dianne’s successful track record as both a front line executive and an independent Director will be valuable to Imagion moving forward as we continue the development of and plan for the commercialization of our MagSense technology.”